TABLE 2.
Factors associated with probability of lack of fidaxomicin treatment response
| Characteristic | No. (%) of patients with: |
Univariate, OR (95% CI); P valuea | Multivariate, OR (95% CI); P value | |
|---|---|---|---|---|
| Treatment failure (n = 18) | Treatment response (n = 32) | |||
| Age > 60 yr | 14 (77.8) | 14 (43.8) | 4.5 (1.21–16.72); 0.04 | 4.7 (0.9–23.4); 0.06 |
| CDI due to NAP1 strain | 10 (55.6) | 11 (35.5) | 2.3 (0.69–7.44); 0.3 | 1.5 (0.36–6.55); 0.6 |
| Severe and severe complicated CDI | 13 (72.2) | 11 (34.4) | 4.9 (1.4–17.56); 0.02 | 5.1 (1.02–25.46); <0.05 |
| Fever when fidaxomicin therapy commenced | 5 (27.8) | 3 (9.4) | 3.7 (0.77–17.94); 0.1 | 2.6 (0.27–25.48); 0.4 |
| Fidaxomicin in combination with other anti-CDI drugsb | 11 (61.1) | 7 (21.9) | 5.6 (1.58–19.87); 0.014 | 4.9 (0.95–25.43); 0.06 |
| CCU level of care during fidaxomicin treatment | 8 (44.4) | 12 (37.5) | 1.3 (0.412–4.31); 0.8 | 0.8 (0.12–3.74); 0.6 |
a
OR, odds ratio; CI, confidence interval.
b
Including metronidazole (n = 9), oral vancomycin (n = 4), or both (n = 5).